Dr Verma's lab is focused on studying the molecular pathogenesis of myelodysplastic syndromes and identifying targetable pathways in this disease. His work has led to identification of stem cell alterations in MDS and has developed a preclinical rationale for the use of inhibitors of TGF-beta family, IRAK and p38 MAP kinase pathways in this disease. His lab is also involved in epigenomic analysis of other tumors and has devised assays for analysis of cytosine hydroxymethylation and methylation. In addition to these preclinical studies, Dr Verma is the director of a MDS Center of Excellence clinic and is involved in various clinical trials in MDS and AML.